Design of Infusion Schemes for Neuroreceptor Imaging: Application to [(11)C]Flumazenil-PET Steady-State Study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Design of Infusion Schemes for Neuroreceptor Imaging : Application to [(11)C]Flumazenil-PET Steady-State Study. / Feng, Ling; Svarer, Claus; Madsen, Karine; Ziebell, Morten; Dyssegaard, Agnete; Ettrup, Anders; Hansen, Hanne Demant; Lehel, Szabolcs; Yndgaard, Stig; Paulson, Olaf Bjarne; Knudsen, Gitte Moos; Pinborg, Lars Hageman.
In: BioMed Research International, Vol. 2016, 9132840, 2016.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Design of Infusion Schemes for Neuroreceptor Imaging
T2 - Application to [(11)C]Flumazenil-PET Steady-State Study
AU - Feng, Ling
AU - Svarer, Claus
AU - Madsen, Karine
AU - Ziebell, Morten
AU - Dyssegaard, Agnete
AU - Ettrup, Anders
AU - Hansen, Hanne Demant
AU - Lehel, Szabolcs
AU - Yndgaard, Stig
AU - Paulson, Olaf Bjarne
AU - Knudsen, Gitte Moos
AU - Pinborg, Lars Hageman
PY - 2016
Y1 - 2016
N2 - This study aims at developing a simulation system that predicts the optimal study design for attaining tracer steady-state conditions in brain and blood rapidly. Tracer kinetics was determined from bolus studies and used to construct the system. Subsequently, the system was used to design inputs for bolus infusion (BI) or programmed infusion (PI) experiments. Steady-state quantitative measurements can be made with one short scan and venous blood samples. The GABAA receptor ligand [(11)C]Flumazenil (FMZ) was chosen for this purpose, as it lacks a suitable reference region. Methods. Five bolus [(11)C]FMZ-PET scans were conducted, based on which population-based PI and BI schemes were designed and tested in five additional healthy subjects. The design of a PI was assisted by an offline feedback controller. Results. The system could reproduce the measurements in blood and brain. With PI, [(11)C]FMZ steady state was attained within 40 min, which was 8 min earlier than the optimal BI (B/I ratio = 55 min). Conclusions. The system can design both BI and PI schemes to attain steady state rapidly. For example, subjects can be [(11)C]FMZ-PET scanned after 40 min of tracer infusion for 40 min with venous sampling and a straight-forward quantification. This simulation toolbox is available for other PET-tracers.
AB - This study aims at developing a simulation system that predicts the optimal study design for attaining tracer steady-state conditions in brain and blood rapidly. Tracer kinetics was determined from bolus studies and used to construct the system. Subsequently, the system was used to design inputs for bolus infusion (BI) or programmed infusion (PI) experiments. Steady-state quantitative measurements can be made with one short scan and venous blood samples. The GABAA receptor ligand [(11)C]Flumazenil (FMZ) was chosen for this purpose, as it lacks a suitable reference region. Methods. Five bolus [(11)C]FMZ-PET scans were conducted, based on which population-based PI and BI schemes were designed and tested in five additional healthy subjects. The design of a PI was assisted by an offline feedback controller. Results. The system could reproduce the measurements in blood and brain. With PI, [(11)C]FMZ steady state was attained within 40 min, which was 8 min earlier than the optimal BI (B/I ratio = 55 min). Conclusions. The system can design both BI and PI schemes to attain steady state rapidly. For example, subjects can be [(11)C]FMZ-PET scanned after 40 min of tracer infusion for 40 min with venous sampling and a straight-forward quantification. This simulation toolbox is available for other PET-tracers.
KW - Adult
KW - Carbon Radioisotopes
KW - Feedback
KW - Female
KW - Flumazenil
KW - Humans
KW - Infusions, Intravenous
KW - Male
KW - Metabolome
KW - Middle Aged
KW - Models, Biological
KW - Positron-Emission Tomography
KW - Sensory Receptor Cells
KW - Time Factors
KW - Young Adult
KW - Clinical Trial
KW - Journal Article
U2 - 10.1155/2016/9132840
DO - 10.1155/2016/9132840
M3 - Journal article
C2 - 27123457
VL - 2016
JO - BioMed Research International
JF - BioMed Research International
SN - 2314-6133
M1 - 9132840
ER -
ID: 174015095